Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Xylometazoline
Drug ID BADD_D02641
Description Xylometazoline is an imidazoline derivative [A228523] with sympathomimetic and nasal decongestant activity. Xylometazoline works by binding to alpha (α)-adrenergic receptors to cause vasoconstriction of nasal blood vessels.[A228508] Xylometazoline is available in over-the-counter (OTC) nasal sprays or drops to temporarily relieve nasal congestion due to cold, hay fever or other respiratory allergies. In some countries, it is available as combination products with [ipratropium], [domiphen], or [dexpanthenol].
Indications and Usage Xylometazoline is indicated for the temporary relief of nasal congestion due to cold, hay fever or other respiratory allergies.[L31598]
Marketing Status approved; investigational
ATC Code R01AA07; R01AB06; S01GA03
DrugBank ID DB06694
KEGG ID D08684
MeSH ID C009695
PubChem ID 5709
TTD Drug ID D0Y4DY
NDC Product Code Not Available
UNII WPY40FTH8K
Synonyms xylometazoline | 2-(4'-tert-butyl-2',6'-dimethylphenylmethyl)imidazoline | Balkis | Chlorohist-LA | Decongest | espa-rhin | Gelonasal | Idasal | Idril N | Nasan | Imidin | Nasengel AL | Nasentropfen AL | Nasenspray AL | NasenGel ratiopharm | NasenSpray ratiopharm | NasenTropfen ratiopharm | Novorin | Otradrops | Otraspray | Otrivin | Otrivin Mentol | Otriven | Rapako | schnupfen endrine | Snup | stas | xylometazoline hydrochloride | xylometazoline monohydrochloride | Amidrin
Chemical Information
Molecular Formula C16H24N2
CAS Registry Number 526-36-3
SMILES CC1=CC(=CC(=C1CC2=NCCN2)C)C(C)(C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anosmia22.04.03.006; 17.04.04.001--
Application site reaction12.07.01.006; 08.02.01.006--Not Available
Burning sensation17.02.06.001; 08.01.09.029--Not Available
Condition aggravated08.01.03.004--Not Available
Dementia19.20.02.001; 17.03.01.001--Not Available
Dependence19.07.06.008--Not Available
Diabetes mellitus14.06.01.001; 05.06.01.001--Not Available
Drug abuse19.07.06.010--Not Available
Drug dependence19.07.06.011--Not Available
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspnoea02.11.05.003; 22.02.01.004--
Epistaxis22.04.03.001; 24.07.01.005--
Insomnia19.02.01.002; 17.15.03.002--
Nasal congestion22.04.04.001--
Nasal oedema22.04.03.012--Not Available
Neoplasm malignant16.16.01.001--Not Available
Palpitations02.11.04.012--
Panic reaction19.06.04.003--Not Available
Parosmia22.04.03.007; 17.04.04.002--Not Available
Rebound effect08.06.02.009--Not Available
Scab23.03.03.004--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Therapeutic response decreased08.06.01.016--Not Available
Therapeutic response unexpected08.06.01.001--Not Available
Throat irritation22.12.03.029; 07.05.05.037--Not Available
Withdrawal syndrome19.07.06.023; 08.06.02.012--Not Available
Rhinalgia22.12.03.020--Not Available
Nasal discomfort22.12.03.012--Not Available
Cardiac disorder02.11.01.003--Not Available
Inflammation10.02.01.089; 08.01.05.007--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages